JPMorgan Chase & Co. (NYSE:JPM) CEO Is Ill, Won’t Cede Reins Of The Bank

Alan Masterson - July 8, 2014

Boston, MA 07/08/2014 (wallstreetpr) – Jamie Dimon, the long-serving CEO of JPMorgan Chase & Co. (NYSE:JPM), has throat cancer but will continue running the company even as he undergoes treatment.

The treatment of the CEO is expected to last about eight weeks. He will receive treatment at Memorial Sloan Kettering Cancer Center.

The CEO told employees that his condition was curable because doctors confirmed that the cancer was confined to its “original site.” Dimon is 58 and recently marked 10 years at the helm of the largest bank in the U.S.

His tenure at the bank has been marked with numerous successes such as the ability of the bank to shake off the impact of the financial meltdown and to emerge from the problem stronger than its rivals.

Succession plan

It has emerged that the board of directors had already discussed various succession plans even before the diagnosis of Mr. Dimon. The board established a short-term, medium-term and long-term plans for the CEO succession, according to the bank’s spokesman, Joseph Evangelisti.

The potential successors considered in the plan included Mary Erdoes, the head of asset management and Gordon Smith, who runs the consumer bank business. The inclusion of Mr. Smith in the succession plan further validated the fact that consumer banking is becoming more prominent at JPMorgan Chase & Co. (NYSE:JPM) as the bank shifts away from complex deal-making that was once the hallmark of Wall Street.

Loss of executives

Although JPMorgan Chase & Co. (NYSE:JPM) has managed to correct its balance sheet following the devastation of the deep recession in 2008 and 2009, the bank has lost big money and talents in the recent past. For example, the company has suffered nearly $20 billion in regulatory settlement because of its dealings in questionable mortgage-backed securities.

As if that is not enough, JPMorgan Chase & Co. (NYSE:JPM) has lost more than 10 senior executives in the last two years alone. Those included Michael J. Cavanagh who left to join private equity firm Carlyle Group. He was once considered an inheritor to CEO Dimon.

Alan Masterson

Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email ([email protected]) or his Google+ page (https://plus.google.com/103338576216002376250).

Leave a Reply

Your email address will not be published. Required fields are marked *

Sign Up To Get Our Latest Stocks Alerts